Tested Applications
| Positive WB detected in | LNCaP cells, human liver tissue, mouse kidney tissue, rat kidney tissue |
| Positive IHC detected in | human prostate cancer tissue, human colon cancer tissue, human gliomas tissue, mouse kidney tissue, rat kidney tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | LNCaP cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:4000 |
| Immunohistochemistry (IHC) | IHC : 1:500-1:2000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
13163-1-AP targets PSMA/GCPII in WB, IHC, IF/ICC, ELISA, Blocking assay applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, mouse, rat, monkey |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag3812 Product name: Recombinant human FOLH1 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 45-385 aa of BC025672 Sequence: SSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGG Predict reactive species |
| Full Name | folate hydrolase (prostate-specific membrane antigen) 1 |
| Calculated Molecular Weight | 719 aa, 81 kDa |
| Observed Molecular Weight | 100 kDa, 120 kDa |
| GenBank Accession Number | BC025672 |
| Gene Symbol | PSMA |
| Gene ID (NCBI) | 2346 |
| RRID | AB_2106442 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q04609 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
PSMA(Prostate-specific membrane antigen) is also named as FOLH1, FOLH, NAALAD1, PSM and belongs to the peptidase M28 family. PSMA is a 100-120 kDa integral transmembrane glycoprotein, considered to be a highly specific marker of the prostate gland, and has successfully been used as a marker of circulating prostatic epithelial cells(PMID:10074909; 15680901). It is involved in conversion of the major neurotransmitter (NAAG) to NAA and free glutamate. It has 8 isoforms produced by alternative splicing.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for PSMA/GCPII antibody 13163-1-AP | Download protocol |
| IHC protocol for PSMA/GCPII antibody 13163-1-AP | Download protocol |
| WB protocol for PSMA/GCPII antibody 13163-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
PSMA/GCPII Polyclonal antibody (Cat# 13163-1-AP) has 20 citations spanning journals including Nature Communications, Theranostics, Biomaterials, Journal of Controlled Release, ACS Sensors, Journal of Nuclear Medicine, International Journal of Nanomedicine, European Urology Oncology, and Cell Stem Cell. Research fields primarily cover prostate cancer diagnosis and therapy, PSMA-targeted molecular imaging, nanomedicine, radiopharmaceuticals, and immunotherapy, with some applications in neuroscience (calcium signaling, tau pathology).
| Species | Application | Title |
|---|---|---|
Theranostics Dual targeting PET tracer [68Ga]Ga-PSFA-01 in patients with prostate cancers: A pilot exploratory study | ||
Biomaterials Genetically modified extracellular vesicles loaded with activated gasdermin D potentially inhibit prostate-specific membrane antigen-positive prostate carcinoma growth and enhance immunotherapy | ||
J Control Release PSMA-targeted nanoparticles for specific penetration of blood-brain tumor barrier and combined therapy of brain metastases. | ||
Biosens Bioelectron PAM-assembled CRISPR-Cas12a activation-based fluorescent and colorimetric dual-modal biosensor for detecting prostate cancer exosomes. | ||
Adv Healthc Mater PSMA-Targeting Imprinted Nanogels for Prostate Tumor Localization and Imaging |
